O Shaughnessy Asset Management LLC Sells 16,977 Shares of Sanofi (NASDAQ:SNY)

O Shaughnessy Asset Management LLC trimmed its position in Sanofi (NASDAQ:SNY) by 12.8% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 115,257 shares of the company’s stock after selling 16,977 shares during the period. O Shaughnessy Asset Management LLC’s holdings in Sanofi were worth $5,559,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in the company. Abel Hall LLC grew its holdings in shares of Sanofi by 1.8% during the fourth quarter. Abel Hall LLC now owns 10,990 shares of the company’s stock valued at $530,000 after buying an additional 194 shares during the last quarter. Providence Capital Advisors LLC boosted its stake in Sanofi by 0.4% during the 4th quarter. Providence Capital Advisors LLC now owns 55,001 shares of the company’s stock valued at $2,653,000 after purchasing an additional 201 shares during the last quarter. Keudell Morrison Wealth Management increased its holdings in Sanofi by 1.7% during the 4th quarter. Keudell Morrison Wealth Management now owns 12,928 shares of the company’s stock worth $624,000 after purchasing an additional 217 shares in the last quarter. Bailard Inc. raised its stake in shares of Sanofi by 1.4% in the fourth quarter. Bailard Inc. now owns 16,359 shares of the company’s stock worth $789,000 after purchasing an additional 220 shares during the last quarter. Finally, Old Port Advisors lifted its holdings in shares of Sanofi by 0.6% in the fourth quarter. Old Port Advisors now owns 36,704 shares of the company’s stock valued at $1,770,000 after purchasing an additional 232 shares in the last quarter. 14.04% of the stock is owned by institutional investors and hedge funds.

Sanofi Trading Down 2.0 %

NASDAQ SNY opened at $54.34 on Wednesday. The business’s fifty day moving average is $55.28 and its 200-day moving average is $52.73. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.46 and a quick ratio of 1.14. The stock has a market capitalization of $137.91 billion, a price-to-earnings ratio of 21.82, a PEG ratio of 1.01 and a beta of 0.58. Sanofi has a one year low of $45.22 and a one year high of $60.12.

Sanofi (NASDAQ:SNY) last released its earnings results on Thursday, January 30th. The company reported $0.70 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. Equities research analysts predict that Sanofi will post 4.36 EPS for the current year.

Analyst Ratings Changes

Several brokerages recently issued reports on SNY. Sanford C. Bernstein upgraded Sanofi to a “strong-buy” rating in a report on Thursday, January 30th. StockNews.com downgraded shares of Sanofi from a “buy” rating to a “hold” rating in a report on Thursday, December 12th. The Goldman Sachs Group assumed coverage on shares of Sanofi in a report on Friday, March 21st. They set a “neutral” rating and a $65.00 price target on the stock. Finally, Deutsche Bank Aktiengesellschaft upgraded shares of Sanofi from a “sell” rating to a “hold” rating in a research note on Thursday, January 30th. Three research analysts have rated the stock with a hold rating, one has assigned a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $62.50.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.